EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MEG3 Promoter Methylation and F11 Receptor (F11R) Overexpression Define a High-Risk Subtype of Diabetic Pancreatic Cancer

Keisuke Yamazaki, Hiroki Mizukami, Takahiro Yamada, Yutaro Hara, Hiroaki Tamba, Yota Tatara, Zhenchao Wang, Akiko Itaya, Hanae Kushibiki, Masaki Ryuzaki, Takanori Sasaki, Hidefumi Ruike und 5 weitere

Modern Pathology · 2026-02 · 39 (2) · 100953

DOI: 10.1016/j.modpat.2025.100953 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-02. Verfasst von Keisuke Yamazaki und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, Biomedical Research Center, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan;…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Pancreatic Neoplasms, DNA Methylation, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-standing diabetes mellitus (long-DM) (≧3 years) is associated with worse clinical outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). Emerging evidence suggests that epigenetic alterations may contribute to this association; however, the underlying mechanisms remain largely unclear. This study aimed to elucidate the role of the tumor-suppressive long noncoding RNA maternally expressed gene 3 (MEG3) and related molecules in the development of PDAC with long-DM. A total of 117 patients who underwent surgical resection for PDAC at Hirosaki University Hospital were retrospectively analyzed. Histopathological assessment followed World Health Organization criteria and the Union for International Cancer Control tumor-node-metastasis classification. Promoter methylation of MEG3 was assessed via methylation-specific PCR using formalin-fixed paraffin-embedded tissue. MEG3 expression levels were assessed by real-time quantitative PCR. Additionally, proteomic profiling was performed using liquid chromatography-tandem mass spectrometry on formalin-fixed paraffin-embedded tissue samples. Among the 117 cases with PDAC, patients with long-DM exhibited significantly poorer tumor differentiation and reduced cancer-specific survival. MEG3 promoter methylation was more prevalent in patients with long-DM. MEG3 methylation was correlated with reduced MEG3 expression, increased venous invasion, higher recurrence rates, and worse prognosis. Proteomic analysis and protein structure prediction tool revealed F11 receptor (F11R) as a potential downstream effector of MEG3. F11R protein expression levels were evaluated using semiquantitative immunohistochemistry. Higher F11R expression was observed in patients with long-DM, correlating with poor histologic differentiation and unfavorable outcomes. Patients with PDAC showing simultaneous MEG3 methylation and F11R high expression were more likely to have long-DM, with additive effects of these changes and tumor recurrence. Our results demonstrated that MEG3 and its potential downstream regulator, F11R, could be involved in PDAC progression, particularly in patients with long-DM. The findings underscore the clinical significance of epigenetic regulation in DM-related PDAC, suggesting novel targets, such as MEG3 and F11R, for potential therapeutic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingPancreatic NeoplasmsDNA MethylationCarcinoma, Pancreatic DuctalReceptors, ThrombinDiabetes MellitusHumansFemaleMaleMiddle AgedAgedPromoter Regions, GeneticRetrospective StudiesBiomarkers, Tumor

Stichwörter der Autor:innen

diabetes mellitusepigeneticslincRNApancreatic ductal adenocarcinomaproteomics

Substanzen

RNA, Long NoncodingMEG3 non-coding RNA, humanBiomarkers, TumorReceptors, Thrombin

Autor:innen und Institutionen

  • Department of Pathology and Molecular Medicine, Biomedical Research Center, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Gastroenterological Surgery, Hirosaki University Gradua…
  • Department of Pathology and Molecular Medicine, Biomedical Research Center, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan. Electronic address: hirokim@hirosaki-u.ac.jp.
  • Department of Stress Response Science, Biomedical Research Center, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
  • Department of Pathology and Molecular Medicine, Biomedical Research Center, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
  • Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.

Zitieren

APA

Yamazaki, K., Mizukami, H., Yamada, T., Hara, Y., Tamba, H., Tatara, Y., Wang, Z., Itaya, A., Kushibiki, H., Ryuzaki, M., Sasaki, T., Ruike, H., Ogasawara, S., Tu, Y., Ishido, K., Itoh, K., & Hakamada, K. (2026). MEG3 Promoter Methylation and F11 Receptor (F11R) Overexpression Define a High-Risk Subtype of Diabetic Pancreatic Cancer. Modern Pathology, 39(2), 100953. https://doi.org/10.1016/j.modpat.2025.100953

Vancouver

Yamazaki K, Mizukami H, Yamada T, Hara Y, Tamba H, Tatara Y, et al. MEG3 Promoter Methylation and F11 Receptor (F11R) Overexpression Define a High-Risk Subtype of Diabetic Pancreatic Cancer. Modern Pathology. 2026;39(2):100953. doi:10.1016/j.modpat.2025.100953

BibTeX
@article{Yamazaki2026,
  author = {Yamazaki, Keisuke and Mizukami, Hiroki and Yamada, Takahiro and Hara, Yutaro and Tamba, Hiroaki and Tatara, Yota and Wang, Zhenchao and Itaya, Akiko and Kushibiki, Hanae and Ryuzaki, Masaki and Sasaki, Takanori and Ruike, Hidefumi and Ogasawara, Saori and Tu, Yi and Ishido, Keinosuke and Itoh, Ken and Hakamada, Kenichi},
  title = {MEG3 Promoter Methylation and F11 Receptor (F11R) Overexpression Define a High-Risk Subtype of Diabetic Pancreatic Cancer},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {2},
  pages = {100953},
  doi = {10.1016/j.modpat.2025.100953}
}
Kostenlos starten →